+1 877 705 191424 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 12Years +
All Genders
ID04883905

ELEVATE A Global Patient Registry to Track the Natural History and Real-World Treatment of Acute Hepatic Porphyria

Led by Alnylam Pharmaceuticals · Updated on 2026-04-27

150

Participants Needed

30

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are conducting a global patient registry to better understand the natural history and real-world clinical management of patients with Acute Hepatic Porphyria AHP. This observational study also aims to gather information on the real-world safety and effectiveness of givosiran and other approved treatments for AHP. The registry is sponsored by Alnylam Pharmaceuticals and includes patients diagnosed with AHP. Participants with AHP will be enrolled and managed according to their usual clinical care without any assigned interventions by the study. The study collects data over time to observe how patients are treated in routine practice and how their condition progresses. There are no experimental treatments given as part of this registry. During the study, researchers will track the occurrence of selected events of interest related to AHP for up to six years. They will also monitor the annual rate of porphyria attacks and assess patients quality of life using the 12-Item Short Form Health Survey Version 2. Participants will be followed prospectively to provide ongoing information about their health and treatment outcomes.

CONDITIONS

Brief Title

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Research Team

A

Alnylam Clinical Trial Information Line

A

Alnylam Clinical Trial Information Line

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here